India, Aug. 25 -- Polaryx Therapeutics, Inc. (PLYX), a clinical-stage biotechnology company developing therapies for rare pediatric lysosomal storage disorders (LSDs), on Tuesday provided an operational readiness update for SOTERIA, its phase 2 basket trial evaluating lead candidate PLX-200 across four rare pediatric LSDs, stating that it remains on track to initiate the trial in the fourth quarter of 2026.
According to the company, in collaboration with its contract research organisation (CRO), it continues to advance clinical trial start-up activities and remains focused on initiating SOTERIA in the fourth quarter of 2026. SOTERIA is a phase 2, open-label, multicenter basket trial designed to evaluate the safety, tolerability, pharmacoki...